NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Oruka Therapeutics, Inc. (ORKA) Stock Analysis

Oruka Therapeutics, Inc. (ORKA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ORKA

$79.92

+$0.83 (+1.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ORKA with… →

ORKA Key Statistics

As of Oct 21, 2026
Trading
Open
$79.97
Previous Close
$79.09
Day's Range
79.48–81.75
52-Week Range
25.11–115.52
Volume
953.37K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.11
Valuation
Market Cap
$5.29B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.04
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$105.43M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.21M
1-Year Return
+192.11%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
878.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ORKA closed at $79.92, +192.11% over 1 year.

Oruka Therapeutics, Inc. (ORKA) has a market capitalization of $5.29B.

ORKA Stock Return by Calendar Year

Oruka Therapeutics, Inc. (ORKA) 10-year return: what $10,000 became

1 year
$10,000 $29,211
+192.11%
5 years
$10,000 $44,705
+347.05%
10 years
$10,000 $2,730
−72.70%

If you had invested $10,000 in Oruka Therapeutics, Inc. (ORKA) 10 years ago, at the close on October 21, 2016, it would have been worth $2,730 at the close on October 21, 2026: −72.70% in total, −12.18% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+163.68%
2025+56.32%
2024+76.73%
2023−28.27%
2022+10.23%
2021−46.38%
2020−29.77%
2019−3.87%
2018−75.56%
2017−52.63%
2016 (partial year)−7.17%

As of October 21, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Oruka Therapeutics, Inc. (ORKA) carries a market capitalisation of $5.29B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 68.

ORKA last closed at $79.92 on October 21, 2026. That is +$0.83 (+1.05%) against the previous close. The 52-week range on file runs from $25.11 to $115.52. The latest close sits 218.28% above that 52-week low.

Financial Health

In fiscal 2025, Oruka Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $105.43M. Earnings per share on a trailing basis come to −2.04.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.11. Daily returns over the trailing 10 years annualize to a volatility of 152.75%. The trailing one-year total return is +192.11%. Measured over 10 years, that is −12.18% a year compounded.

Growth & Income

The latest dividend on file for ORKA dates from 2024.

The strongest complete calendar year on file is 2024 at +76.73%; the weakest is 2018 at −75.56%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is +163.68%.

Peer Comparison

Oruka Therapeutics, Inc. (ORKA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Oruka Therapeutics, Inc. ORKA $5.29B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Oruka Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Visit website →